Self-funded and founded by WHO and Sweden
UMC's work is governed by an agreement between WHO and the Swedish government. UMC independently funds its operations and the WHO Programme for International Drug Monitoring.
UMC was founded based on an agreement between WHO and the Swedish government in 1978, and each appoint three members and alternates to UMC’s board. The CEO of UMC reports to the board.
Since May 2019, the board has been chaired by Dr Filippa Nyberg, Senior Consultant at Karolinska University Hospital, and Associate Professor at the Karolinska Institute.
UMC's senior leadership team guides the work of UMC on a day-to-day basis.
UMC is independent and self-funded. We finance our operations by selling pharmacovigilance products and services to a range of external bodies, most notably the WHODrug Global portfolio of products. Funding our own operations ensures intellectual and scientific independence, sustainability, and freedom to pursue our vision.
We do not receive other funding from external sources, except for specific project grants.